Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



Promising results for lenalidomide plus dexamethasone in myeloma

A trial involving more than 1,600 patients with multiple myeloma showed improvement in progression-free survival with a new combination therapy.

Plasma cells in multiple myeloma patient

Source: Dr Erhabor Osaro / Wikimedia Commons

New combination therapy for multiple myeloma patients shows promise (plasma cells in a multiple myeloma patient pictured)

Triple therapy with melphalan, prednisone and thalidomide (MPT) is the current standard of care for patients with myeloma who are ineligible for stem-cell transplantation.

This may change following publication in The New England Journal of Medicine (online, 4 September 2014)[1] of data on a promising new combination therapy, lenalidomide plus dexamethasone (LD).

The “FIRST” trial included 1,623 patients newly diagnosed with multiple myeloma and ineligible for stem-cell therapy. At a median follow-up of 37 months, progression-free survival was 25.5 months with continuous LD, 20.7 months with 18 cycles of LD and 21.2 months with MPT. Continuous LD was superior to MPT for all secondary efficacy endpoints, including overall survival, and was associated with a lower frequency of grade 3 or 4 adverse events. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066435

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Community Pharmacy Handbook

    Community Pharmacy Handbook

    Community Pharmacy Handbook is a survival guide for community pharmacists and students, answering your practical questions. Includes case studies.

    £33.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • multiple-myeloma-15

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.